380 institutions hold shares in Iovance Biotherapeutics Inc. (IOVA), with 936.26k shares held by insiders accounting for 0.64% while institutional investors hold 106.19% of the company’s shares. The shares outstanding are 138.30M, and float is at 135.58M with Short Float at 15.72%. Institutions hold 105.51% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 15.3 million shares valued at $709.82 million. The investor’s holdings represent 10.41% of the IOVA Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 11.87 million shares valued at $550.55 million to account for 8.07% of the shares outstanding. The other top investors are Perceptive Advisors Llc which holds 9.17 million shares representing 6.24% and valued at over $425.32 million, while Blackrock Inc. holds 6.13% of the shares totaling 9.0 million with a market value of $417.72 million.
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is -32.97% lower on its value in year-to-date trading and has touched a low of $24.67 and a high of $54.21 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IOVA stock was last observed hovering at around $30.17 in the last trading session, with the day’s gains setting it 0.93% off its average median price target of $54.00 for the next 12 months. It is also 67.94% off the consensus price target high of $97.00 offered by 13 analysts, but current levels are 11.14% higher than the price target low of $35.00 for the same period.
Currently trading at $31.10, the stock is 1.93% and -12.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.71 million and changing 3.08% at the moment leaves the stock -15.64% off its SMA200. IOVA registered -15.10% loss for a year compared to 6-month loss of -14.47%. The firm has a 50-day simple moving average (SMA 50) of $35.43 and a 200-day simple moving average (SMA200) of $40.00.
The stock witnessed a -4.22% gain in the last 1 month and extending the period to 3 months gives it a -36.41%, and is 3.70% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.88% over the week and 6.57% over the month.
Distance from 52-week low is 26.06% and -42.63% from its 52-week high.
Iovance Biotherapeutics Inc. (IOVA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Iovance Biotherapeutics Inc. (IOVA) is a “Buy”. 13 analysts offering their recommendations for the stock have an average rating of 1.70, where 1 rate it as a Hold and 1 think it is a “Overweight”. 11 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Iovance Biotherapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.49.The EPS is expected to shrink by -18.10% this year.
Iovance Biotherapeutics Inc. (IOVA): Who are the competitors?
The company’s main competitors (and peers) include Expeditors International of Washington Inc. (EXPD) that is trading 58.22% up over the past 12 months. Forward Air Corporation (FWRD) is 77.92% up on the 1-year trading charts. Short interest in the company’s stock has fallen -52.5% from the last report on Mar 30, 2021 to stand at a total of 21.32 million short shares sold with a short interest ratio of 8.59.